What side effects do patients commonly report with Perjeta (pertuzumab)?
Perjeta (pertuzumab) is commonly discussed alongside trastuzumab and chemotherapy for HER2-positive breast cancer. The most frequently seen side effects reported in connection with Perjeta-based treatment include infusion-related reactions and diarrhea, along with effects related to the overall regimen (chemotherapy and trastuzumab).
Patients should also be monitored for heart-related safety issues because HER2-targeted therapies can affect cardiac function.
What infusion reactions can happen after getting Perjeta?
Infusion reactions can occur during or after Perjeta infusions. These reactions can include symptoms such as chills, fever, shortness of breath, flushing, rash, or other allergic-type symptoms. Clinicians typically watch patients during infusions and may slow or stop treatment if a reaction occurs.
What gastrointestinal side effects (like diarrhea) are associated with Perjeta?
Diarrhea is one of the notable side effects associated with Perjeta. Patients may be advised to report ongoing or severe diarrhea quickly, especially if it leads to dehydration or inability to drink fluids.
Does Perjeta affect the heart? What cardiac monitoring is needed?
Yes. Because Perjeta is used for HER2-positive disease, cardiac monitoring is part of standard care when patients receive HER2-targeted treatments. Heart function is typically assessed before treatment and periodically during therapy, and clinicians may hold treatment or adjust therapy if cardiac function declines.
Who might be at higher risk for serious complications?
Risk can vary by patient factors and by the rest of the treatment regimen (particularly the chemotherapy used with Perjeta). People with prior heart conditions, reduced baseline cardiac function, or prior therapy that affected the heart may have higher risk of cardiac complications and usually require closer monitoring.
When should patients seek urgent care?
Seek urgent medical attention for severe symptoms such as trouble breathing, swelling of the face or throat, chest pain, fainting, or severe allergic-type reactions during or shortly after an infusion. Also seek prompt care for severe diarrhea, dehydration symptoms (dizziness, very low urine output), or signs of infection, depending on how chemotherapy is being combined with Perjeta.
Sources
- DrugPatentWatch.com (Perjeta/pertuzumab related reference hub): https://www.drugpatentwatch.com/